EYEN.png
Eyenovia Provides Update on Restructuring Efforts
22 nov. 2024 07h00 HE | Eyenovia, Inc.
Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic...
EYEN.png
Eyenovia Provides Update on Phase 3 CHAPERONE Study
15 nov. 2024 07h00 HE | Eyenovia, Inc.
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and...
EYEN.png
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12 nov. 2024 16h05 HE | Eyenovia, Inc.
Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of...
EYEN.png
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
07 nov. 2024 07h00 HE | Eyenovia, Inc.
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet...
EYEN.png
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
23 oct. 2024 07h00 HE | Eyenovia, Inc.
Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives ...
EYEN.png
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
16 oct. 2024 07h00 HE | Eyenovia, Inc.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo,...
EYEN.png
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
01 oct. 2024 07h00 HE | Eyenovia, Inc.
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of...
EYEN.png
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
27 sept. 2024 08h30 HE | Eyenovia, Inc.
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in...
EYEN.png
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
26 sept. 2024 07h00 HE | Eyenovia, Inc.
NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate...
EYEN.png
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.
05 sept. 2024 07h00 HE | Eyenovia, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in development for the...